First patients sought for groundbreaking lung cancer cell therapy trial
NCT ID NCT07249879
Summary
This is the first-ever study in people to test the safety and early effects of an experimental cell therapy called GC511B for a hard-to-treat type of lung cancer. The trial will enroll 55 adults whose small cell lung cancer has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to target the cancer, and reinfuse them to see if they are safe and can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
Beijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.